ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) posted its earnings results on Monday. The company reported ($1.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.84) by ($0.18), FiscalAI reports.
ENDRA Life Sciences Trading Up 0.5%
Shares of NDRA traded up $0.02 during trading hours on Monday, reaching $4.43. 4,492 shares of the stock traded hands, compared to its average volume of 51,423. The stock has a fifty day simple moving average of $5.32 and a 200 day simple moving average of $4.82. ENDRA Life Sciences has a 52 week low of $2.96 and a 52 week high of $6.95. The company has a market cap of $6.64 million, a price-to-earnings ratio of -0.69 and a beta of -0.07.
Analysts Set New Price Targets
Separately, Weiss Ratings cut ENDRA Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, November 2nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.00.
Read Our Latest Report on NDRA
About ENDRA Life Sciences
ENDRA Life Sciences is a medical technology company developing imaging tools for the assessment of liver disease. Its technology is designed to provide clinicians with a non-invasive way to evaluate liver tissue and support the monitoring of conditions such as fatty liver disease. The company’s lead platform, TAEUS (Thermo-Acoustic Enhanced Ultrasound), combines radiofrequency energy with ultrasound to measure tissue characteristics, including liver fat. ENDRA is developing the system as an alternative or complement to existing approaches to liver assessment.
Further Reading
- Five stocks we like better than ENDRA Life Sciences
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for ENDRA Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ENDRA Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
